Evidence map›Paper›PMID 29056493›Full record

ReviewSchizophrenia research2018

Genetic analysis of deep phenotyping projects in common disorders.

Elliot S Gershon, Godfrey Pearlson, Matcheri S Keshavan, Carol Tamminga, Brett Clementz, Peter F Buckley, Ney Alliey-Rodriguez, Chunyu Liu, John A Sweeney, Sarah Keedy and 5 more

Abstract readReview
In one paragraph

Review in Schizophrenia research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  4. Review
  5. Article
  6. Cardiovascular Precision Medicine in the Genomics Era.JACC. Basic to translational science · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Elliot S GershonDepartment of Psychiatry, Department of Human Genetics, University of Chicago, United States. Electronic address: egershon@yoda.bsd.uchicago.edu.
Godfrey PearlsonYale University Departments of Psychiatry & Neuroscience, Hartford, CT, United States; Olin Neuropsychiatry Research Center, Institute of Living, Hartford, Connecticut, USA.
Matcheri S KeshavanHarvard Medical School, Department of Psychiatry, Boston, MA, United States.
Carol TammingaDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Brett ClementzDepartment of Psychology, University of Georgia, Athens, GA, United States.
Peter F BuckleySchool of Medicine Virginia Commonwealth University (VCU), Richmond, VA, United States.
Ney Alliey-RodriguezUniversity of Chicago, Department of Psychiatry and Behavioral Neurosciences, Chicago, IL, United States.
Chunyu LiuUniversity of Illinois at Chicago, Chicago, IL, United States.
John A SweeneyDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, United States; University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, Cincinnati, OH, United States.
Sarah KeedyUniversity of Chicago, Department of Psychiatry and Behavioral Neurosciences, Chicago, IL, United States.
Shashwath A MedaYale University Departments of Psychiatry & Neuroscience, Hartford, CT, United States.
Neeraj TandonBeth Israel Deaconess Medical Center, Dept of Psychiatry, Harvard Medical School, United States.
Rebecca ShafeeBroad Institute of MIT and Harvard, Cambridge, MA, United States; Department of Genetics, Harvard Medical School, United States.
Jeffrey R BishopDepartment of Clinical and Experimental Pharmacology, University of Minnesota, Minneapolis, MN, United States.
Elena I IvlevaDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, United States.

Funding

Bipolar & Schizophrenia Consortium for Parsing Intermediate PhenotypesR01MH077851 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI TAMMINGA, CAROL A · 2007 to 2019
$7.8M
Bipolar & Schizophrenia Consortium for Parsing Intermediate PhenotypesR01MH077945 · NIMH · YALE UNIVERSITY · PI PEARLSON, GODFREY D · 2007 to 2019
$7.6M
Stability of Biotypes: a Longitudinal EvaluationR01MH078113 · NIMH · WAYNE STATE UNIVERSITY · PI KESHAVAN, MATCHERI S. · 2007 to 2019
$6.2M
Stability of Biotypes: a Longitudinal Evaluation (STABLE)R01MH103368 · NIMH · UNIVERSITY OF CHICAGO · PI GERSHON, ELLIOT S, KEEDY, SARAH K · 2015 to 2019
$4.5M
5/5 BIPOLAR-SCHIZOPHRENIA NETWORK FOR INTERMEDIATE PHENOTYPES (B-SNIP) - Resubmission - 1R01MH103366 · NIMH · UNIVERSITY OF GEORGIA · PI CLEMENTZ, BRETT A, GIBBONS, ROBERT D · 2015 to 2019
$3.8M
Bipolar & Schizophrenia Consortium for Parsing Intermediate PhenotypesR01MH077862 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI SWEENEY, JOHN A · 2007 to 2010
$3.1M
COLLABORATIVE STUDY OF BIPOLAR DISORDERR01MH059535 · NIMH · UNIVERSITY OF CHICAGO · PI GERSHON, ELLIOT S · 1998 to 2007
$1.9M
2/5-Clozapine Response and Biomarker Correlates in Low-IEA Biotype-1R01MH124804 · NIMH · UNIVERSITY OF CHICAGO · PI GERSHON, ELLIOT S, KEEDY, SARAH K · 2021 to 2025
$1.8M
Neural Network Biomarkers for Relational Memory and Psychosis in SchizophreniaK23MH102656 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI IVLEVA, ELENA IVANOVNA · 2014 to 2017
$679k
NIMH NIH HHS K23 MH102656NIMH NIH HHS R01 MH059535NIMH NIH HHS R01 MH077851NIMH NIH HHS R01 MH077862NIMH NIH HHS R01 MH077945NIMH NIH HHS R01 MH078113NIMH NIH HHS R01 MH103366NIMH NIH HHS R01 MH103368NIMH NIH HHS R01 MH124804
6 · The paper itself

Abstract

Several studies of complex psychotic disorders with large numbers of neurobiological phenotypes are currently under way, in living patients and controls, and on assemblies of brain specimens. Genetic analyses of such data typically present challenges, because of the choice of underlying hypotheses on genetic architecture of the studied disorders and phenotypes, large numbers of phenotypes, the appropriate multiple testing corrections, limited numbers of subjects, imputations required on missing phenotypes and genotypes, and the cross-disciplinary nature of the phenotype measures. Advances in genotype and phenotype imputation, and in genome-wide association (GWAS) methods, are useful in dealing with these challenges. As compared with the more traditional single-trait analyses, deep phenotyping with simultaneous genome-wide analyses serves as a discovery tool for previously unsuspected relationships of phenotypic traits with each other, and with specific molecular involvements.

Indexed as

Genome-Wide Association StudyGenetic Predisposition to DiseaseGenetic VariationGenotypeHumansMental DisordersPhenotypeFunctional genomicsGenetic analysisImputationMultiple testingPhenotype

Identifiers

PMID29056493
PMCPMC5910299

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.